Cempra is a clinical-stage pharmaceutical company focused on the development of antibacterial products to meet critical medical needs in the treatment of infectious bacterial diseases. The company’s product pipeline includes two leading candidates in advanced clinical development. Solithromycin, Cempra’s first candidate, is currently being evaluated in phase III clinical studies for the treatment of community acquired bacterial pneumonia (CABP) and uncomplicated bacterial urethritis caused by Neisseria gonorrhea and chlamydia. Taksta™, Cempra’s second candidate, is being developed for chronic oral treatment of refractory infections in bones and joints.
Additionally, with funding provided by the Biomedical Advanced Research Development Authority (BARDA), Cempra is currently conducting a phase Ib clinical trial to evaluate solithromycin as a pediatric treatment for respiratory tract infections. This program, which was initiated earlier this year, represents the first development of a pediatric suspension formulation of an antibiotic for the treatment of respiratory tract infections in more than 20 years.
In the first quarter of 2015, Cempra reported positive topline results from its initial phase III clinical trial of solithromycin for the treatment of CABP. According to the report, the product candidate performed on pace or better than the current standard of care in sustainability of clinical response at all studied durations.
“Cempra is off to a great start in 2015 and I am pleased that we have achieved enrollment of 610 patients in the… phase III clinical trial in CABP,” Dr. Prabhavathi Fernandes, president and chief executive officer of Cempra, stated in a news release. “Our initial commercial preparations for solithromycin are also underway as we continue our market research activities to assess the commercial potential for this exciting new antibiotic.”
When commercialized, solithromycin for the treatment of CABP should provide Cempra with a platform to realize sustainable market growth in the future. CABP is currently one of the most commonly diagnosed bacterial infections in the United States, with an estimated five to ten million cases recorded each year. Because many strains of the infection have become resistant to currently-approved antibacterial drugs, the market demand for solithromycin is expected to be immense in the years to come.
The continued development of Cempra’s advanced product pipeline should provide channels for the company to realize improved investor returns. For prospective shareholders, this potential makes Cempra an intriguing investment opportunity in the months ahead. Look for the company to continue making strides toward the eventual commercialization of its leading product candidates in order to bolster its financial growth moving forward.
For more information, visit www.cempra.com
